How does neuroblastoma begin and can we use this knowledge to develop new treatments?
Dissecting the role of MYCN in neuroblastoma initiation
Factors which affect survival following relapse in neuroblastomas
Clinical and biological factors associated with relapse and length of survival following relapse in UK neuroblastomas
A novel laboratory model for neuroblastoma research
Establishment of an in vitro model of neuroblastoma initiation using pluripotent stem cell differentiation
Improving our understanding of immunotherapy in high-risk neuroblastoma
Understanding and improving the mechanism of action of anti-GD2 monoclonal antibody therapy in neuroblastoma
Understanding drug resistance in neuroblastoma to develop personalised treatments
Overcoming drug resistance for efficacious neuroblastoma therapeutics
Can we identify an 'ultra-high-risk' type of neuroblastoma?
A pilot study of expression profiling using RNAseq from formalin fixed neuroblastoma and paired diagnostic and relapsed frozen neuroblastomas.
Understanding the genetics of poor outcome neuroblastoma to improve treatment
A genome wide study of unresectable, MYCN non-amplied, unfavourable histology neuroblastomas in patients older than 18 months of age
Understanding why some children with neuroblastoma have worse survival or respond badly to treatment
Targeting the Fanconi Anaemia pathyway in neuroblastoma
Using genetics to find targets for new drugs to treat relapsed neuroblastoma
Characterisation and validation of recurrently mutated genes in relapsed neuroblastoma as targets for novel therapies